X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the agreement, Kyverna gains access to LentiVector® platform, the first commercially approved lentiviral-based gene delivery system, to use with any Kyverna product, including its anti-CD19 CAR T-cell therapies, KYV-101 and KYV-201 which specifically target CD19.
Lead Product(s): KYV-101
Therapeutic Area: Immunology Product Name: KYV-101
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Kyverna Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement September 20, 2023
Details:
Oxford Biomedica Solutions will provide its full platform offering to support the new partners’ pre-clinical gene therapy programmes, which cover development programmes including CNS, autoimmune disease, oncology, muscular disorder, and rare metabolic disease.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership December 14, 2022
Details:
The LSA grants the new partner a non-exclusive licence to utilise Oxford Biomedica’s LentiVector® platform for its application in their lead CAR-T programme, and puts in place a three-year Clinical Supply Agreement.
Lead Product(s): CAR-T Therapy
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: LSA
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement July 26, 2022
Details:
OTL-203, an investigational hemopoietic stem cell (HSC) gene therapy in development for the potential treatment of mucopolysaccharidosis type I Hurler’s syndrome (MPS-IH).
Lead Product(s): OTL-203
Therapeutic Area: Genetic Disease Product Name: OTL-203
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Orchard Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 26, 2022
Details:
The manufacture of COVID-19 vaccines, Vaxzevria (Recombinant ChAdOx1-S), at Oxford Biomedica’s Oxbox facility is expected to complete in the last quarter of 2022, will be available to AstraZeneca on an as needed basis beyond 2022.
Lead Product(s): Recombinant ChAdOx1-S
Therapeutic Area: Infections and Infectious Diseases Product Name: Vaxzevria
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement July 01, 2022
Details:
Sio intends to return the global rights for AXO-Lenti-PD and that they intend to cease work on this gene therapy programme in Parkinson’s Disease. Sio is currently conducting a Phase 2 SUNRISE-PD trial with AXO-Lenti-PD.
Lead Product(s): AXO-Lenti-PD
Therapeutic Area: Neurology Product Name: OXB-102
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Sio Gene Therapies
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 31, 2022
Details:
Under the terms of the agreement, Oxford Biomedica will receive payments related to the development and manufacturing of lentiviral vectors for use in clinical trials with also allowing for payments for the manufacture and supply of lentiviral vectors for commercial use.
Lead Product(s): Tisagenlecleucel
Therapeutic Area: Oncology Product Name: Kymriah
Highest Development Status: ApprovedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Novartis Pharmaceuticals Corporation
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement December 13, 2021
Details:
Oxford Biomedica announced an 18 month supply agreement in September 2020 under a three year Master Supply and Development Agreement with AstraZeneca for large-scale manufacture of the adenovirus vector-based COVID-19 vaccine, AZD1222.
Lead Product(s): ChAdOx1 nCoV-19
Therapeutic Area: Infections and Infectious Diseases Product Name: AZD1222
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 18, 2021
Details:
PhoreMost will deploy its in-house expertise and next-generation phenotypic screening platform, SITESEEKER®, to identify therapeutic candidates for Oxford Biomedica’s LentiVector® gene therapy delivery system.
Lead Product(s): LentiVector based gene therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Cell and Gene therapy
Recipient: PhoreMost
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 09, 2020
Details:
AXO-Lenti-PD gene therapy demonstrate consistent treatment outcomes including Favorable safety and tolerability profile, with no serious adverse events attributable to gene therapy; Improvement in Hauser diary “Good ON time” and “OFF time” and other outcomes.
Lead Product(s): AXO-Lenti-PD
Therapeutic Area: Neurology Product Name: OXB-102
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Recipient: Sio Gene Therapies
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 29, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
